S
92.95
1.55 (1.70%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Spyre Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-1.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.17 |
|
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 8.71% |
| 机构持股比例 | 106.07% |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合